<DOC>
	<DOCNO>NCT01026233</DOCNO>
	<brief_summary>The purpose study evaluate cardiac safety brentuximab vedotin ( SGN-35 ) patient CD30-positive cancer . The study assess electrical activity heart brentuximab vedotin administration . Patients stable improve disease may receive 1 year brentuximab vedotin treatment .</brief_summary>
	<brief_title>Cardiac Safety Study Brentuximab Vedotin ( SGN-35 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Relapsed refractory CD30positive malignancy Adequate organ function ECOG performance status &lt; 2 Cardiac abnormality ( abnormal rhythm , history significant cardiac event ) Current diagnosis primary cutaneous ALCL Acute chronic graftversushost disease Prior hematopoietic stem cell transplant within specify timeframe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Disease , Hodgkin</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>monomethylauristatin E</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
</DOC>